ongoing

The AXIOMATIC SSP study is a global, phase 2, randomized, double-blind, placebo-controlled, dose-ranging Study of BMS-987177, an oral factor XIa inhibitor, for the prevention of new ischemic stroke or new silent brain infraction in patients receiving aspirin and clopidogrel following acute non-hemorrhagic stroke or transient ischemia attack (TIA).

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to aspirin and clopidogrel is more effective than standard therapy in secondary stroke prevention.

More about this study at: ClinicalTrials.gov.

Study Type

Interventional - Drug

Study Design

Double-blind placebo-controlled dose-ranging RCT

NO. of Countries

28

NO. of Sites

380

NO. of Participants

2350

Study Period

2019 - 2021

Sponsor

Bristol Myers Squibb, Janssen

Bristol-Myers Squibb

Back To Top